| Literature DB >> 30441874 |
Kacper Guglas1,2,3, Tomasz Kolenda4,5,6, Anna Teresiak7, Magda Kopczyńska8,9, Izabela Łasińska10, Jacek Mackiewicz11,12,13, Andrzej Mackiewicz14,15, Katarzyna Lamperska16.
Abstract
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cause of cancer mortality in the world. To improve the quality of diagnostics and patients' treatment, new and effective biomarkers are needed. Recent studies have shown that the expression level of different types of long non-coding RNAs (lncRNAs) is dysregulated in HNSCC and correlates with many biological processes. In this study, the response of lncRNAs in HNSCC cell lines after exposure to irradiation and cytotoxic drugs was examined. The SCC-040, SCC-25, FaDu, and Cal27 cell lines were treated with different radiation doses as well as exposed to cisplatin and doxorubicin. The expression changes of lncRNAs after exposure to these agents were checked by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Target prediction was performed using available online tools and classified into specific biological processes and cellular pathways. The results indicated that the irradiation, as well as chemoexposure, causes changes in lncRNA expression and the effect depends on the cell line, type of agents as well as their dose. After irradiation using the dose of 5 Gy significant dysregulation of 4 lncRNAs, 10 Gy-5 lncRNAs, and 20 Gy-3 lncRNAs, respectively, were observed in all cell lines. Only lncRNAs Zfhx2as was down-regulated in all cell lines independently of the dose used. After cisplatin exposure, 14 lncRNAs showed lower and only two higher expressions. Doxorubicin resulted in lower expressions of eight and increased four of lncRNAs. Common effects of cytotoxic drugs were observed in the case of antiPEG11, BACE1AS, PCGEM1, and ST7OT. Analysis of the predicted targets for dysregulated lncRNAs indicated that they are involved in important biological processes, regulating cellular pathways connected with direct response to irradiation or chemoexposure, cellular phenotype, cancer initiating cells, and angiogenesis. Both irradiation and chemoexposure caused specific changes in lncRNAs expression. However, the common effect is potentially important for cellular response to the stress and survival. Further study will show if lncRNAs are useful tools in patients' treatment monitoring.Entities:
Keywords: cellular stress; chemoresistance; head and neck cancers; long non-coding RNA (lncRNA); radioresistance
Year: 2018 PMID: 30441874 PMCID: PMC6315432 DOI: 10.3390/ncrna4040033
Source DB: PubMed Journal: Noncoding RNA ISSN: 2311-553X
Half maximal inhibitory concentration (IC50) values of cisplatin and doxorubicin for head and neck squamous cell carcinomas (HNSCC) cell lines.
| Cell Line | Cisplatin [μg/mL] | Doxorubicin [μg/mL] |
|---|---|---|
| SCC-040 | 10.67 | 1.54 |
| SCC-25 | 4.49 | 2.70 |
| FaDu | 5.88 | 0.23 |
| Cal27 | 3.42 | 0.63 |
Figure 1Heat map and clustering of 96 lncRNAs after irradiation of head and neck squamous cell carcinoma (HNSCC) cell lines using dose of 5 Gy, 10 Gy, and 20 Gy. Data shown as 2−ΔΔCt (compared to non-irradiated control).
Expression values of HOTAIR, HOXA3as, SNHG5, and Zfhx2as after exposure to 5 Gy irradiation.
| lncRNA | 5 Gy | Control | Regulation | |||
|---|---|---|---|---|---|---|
| Mean Value | SEM | Mean Value | SEM | |||
| HOTAIR | 0.0007863 | 0.0001301 | 0.0003619 | 0.000062 | 0.0284 | Up |
| HOXA3as | 0.003036 | 0.0003097 | 0.001569 | 0.002016 | 0.0313 | Up |
| SNHG5 | 0.02683 | 0.009113 | 0.02062 | 0.008001 | 0.0444 | Down |
| Zfhx2as | 0.004621 | 0.001548 | 0.007150 | 0.0008250 | 0.0415 | Down |
Figure 2Differences in lncRNAs expression: HOTAIR, HOXA3as, SNHG5, and Zfhx2as in HNSCC cell lines after exposure to 5 Gy irradiation. Paired t-test; the graphs show relative expression, mean value with standard error of mean (SEM); * p < 0.05.
Expression values of CAR Intergenic 10, Dio3os, HAR1A, Zfhx2as, and HAR1B after exposure to 10 Gy irradiation.
| lncRNA | 10 Gy | Control | Regulation | |||
|---|---|---|---|---|---|---|
| Mean Value | SEM | Mean Value | SEM | |||
| CAR Intergenic 10 | 0.003959 | 0.0006232 | 0.006326 | 0.000663 | 0.0090 | Down |
| Dio3os | 0.01809 | 0.003639 | 0.02259 | 0.004096 | 0.0137 | Down |
| HAR1A | 0.06480 | 0.01247 | 0.09771 | 0.01660 | 0.0486 | Down |
| Zfhx2as | 0.002828 | 0.0006854 | 0.007150 | 0.0008250 | 0.0174 | Down |
| HAR1B | 0.7414 | 0.1607 | 1.432 | 0.1190 | 0.0116 | Down |
Figure 3Differences in lncRNAs expression: CAR Intergenic 10, Dio3os (family), HAR1A, Zfhx2as, and HAR1B in HNSCC cell lines after exposure to 10 Gy irradiation and in non-irradiated controls. Paired t-test; the graphs show relative expression, mean value with SEM; * p < 0.05; ** p < 0.01.
Expression values of HOXA6as, PTENP1, and Zfhx2as after exposure to 20 Gy irradiation.
| lncRNA | 20 Gy | Control | Regulation | |||
|---|---|---|---|---|---|---|
| Mean Value | SEM | Mean Value | SEM | |||
| HOXA6as | 1.402 | 0.2677 | 4.402 | 0.7998 | 0.0359 | Down |
| Zfhx2as | 0.004668 | 0.0008109 | 0.007150 | 0.0008250 | 0.0399 | Down |
| PTENP1 | 0.001173 | 0.00009963 | 0.0007758 | 0.0001416 | 0.0215 | Up |
Figure 4Differences in lncRNAs expression: HOXA6as, PTENP1, and Zfhx2as in HNSCC cell lines after exposure to 20 Gy irradiation. Paired t-test; the graphs show relative expression, mean value with SEM; * p < 0.05.
Figure 5Heat map and clustering of 96 lncRNAs after cisplatin and doxorubicin exposure of HNSCC cell lines. Data shown as 2−ΔΔCt (compared to non-treated control).
Expression values of changed lncRNAs after exposure to cisplatin.
| lncRNA | Cisplatin | Control | Regulation | |||
|---|---|---|---|---|---|---|
| Mean Value | SEM | Mean Value | SEM | |||
| AIR | 0.0000253 | 0.00001148 | 0.0004905 | 0.0000939 | 0.0216 | Down |
| antiPEG11 | 0.000023 | 0.00002268 | 0.0007075 | 0.0001743 | 0.0346 | Down |
| BACE1AS | 0.001018 | 0.0003542 | 0.005802 | 0.0004859 | 0.0101 | Down |
| CAR Intergenic 10 | 0.001177 | 0.0001425 | 0.006326 | 0.0006632 | 0.0043 | Down |
| DISC2 | 0.002344 | 0.0004130 | 0.003313 | 0.0006576 | 0.0383 | Down |
| MEG3 | 0.0002745 | 0.00003811 | 0.0006915 | 0.0001430 | 0.0450 | Down |
| ncR-uPAR | 0.03412 | 0.03412 | 0.3023 | 0.04289 | 0.0117 | Down |
| PCGEM1 | 0.0004706 | 0.0004705 | 0.006559 | 0.001358 | 0.0347 | Down |
| PRINS | 0.003718 | 0.0004419 | 0.009154 | 0.001596 | 0.0283 | Down |
| PSF Inhibiting RNA | 0.0007353 | 0.0001013 | 0.001011 | 0.0001240 | 0.0093 | Down |
| PTENP1 | 0.0002597 | 0.00004899 | 0.0007758 | 0.0001416 | 0.0326 | Down |
| SNHG6 | 0.003473 | 0.001286 | 0.009557 | 0.001016 | 0.0190 | Down |
| SRA | 0.001234 | 0.0004121 | 0.004215 | 0.0004109 | 0.0352 | Down |
| ST7OT | 0.002699 | 0.002699 | 0.02712 | 0.003087 | 0.0018 | Down |
| IPW | 0.006479 | 0.0009348 | 0.002217 | 0.0002986 | 0.0084 | Up |
| lincRNA-ROR | 0.001588 | 0.0002322 | 0.000008324 | 0.000003423 | 0.0065 | Up |
Figure 6Differences in lncRNAs expression: AIR, antiPEG11, BACE1AS (family), CAR Intergenic 10, DISC2 (family), IPW, MEG3 (family), lincRNA-ROR, ncR-uPAR, PCGEM1, PRINS, PSF Inhibiting RNA, PTENP1, SNHG6, SRA, and ST7OT in HNSCC cell lines after exposure to cisplatin. Paired t-test; the graphs show relative expression, mean value with SEM; * p < 0.05, ** p < 0.01.
Expression values of changed lncRNAs after exposure to doxorubicin.
| lncRNA | Doxorubicin | Control | Regulation | |||
|---|---|---|---|---|---|---|
| Mean Value | SEM | Mean Value | SEM | |||
| antiPEG11 | 0.000008542 | 0.000008388 | 0.0007075 | 0.0001743 | 0.0295 | Down |
| BACE1AS | 0.001765 | 0.0008225 | 0.005802 | 0.0004859 | 0.0461 | Down |
| EgoA | 0.0001311 | 0.0001299 | 8.464 | 1.256 | 0.0067 | Down |
| lincRNA-p21 | 0.000009656 | 0.000008042 | 0.01798 | 0.001301 | 0.0008 | Down |
| Malat1 | 0.002630 | 0.001737 | 0.01547 | 0.005476 | 0.0431 | Down |
| PCGEM1 | 0.0000003499 | 0.0000002346 | 0.006559 | 0.001358 | 0.0169 | Down |
| UM9-5 | 0.001597 | 0.0006579 | 0.007780 | 0.0007437 | 0.0019 | Down |
| ST7OT | 0.00001693 | 0.00001578 | 0.02712 | 0.003087 | 0.0031 | Down |
| Evf1 and EVF2 | 0.03276 | 0.008313 | 0.0003172 | 0.0001031 | 0.0290 | Up |
| lincRNA-SFMBT2 | 0.04731 | 0.007573 | 0.0005287 | 0.0002873 | 0.0086 | Up |
| Nespas | 0.01695 | 0.002727 | 0.01109 | 0.002470 | 0.0255 | Up |
| Zfas1 | 0.2444 | 0.06615 | 0.00002017 | 0.0000069 | 0.0344 | Up |
Figure 7Differences in lncRNAs expression: antiPEG11, BACE1AS (family), EgoA, Evf1 and EVF2, lincRNA-p21, lincRNA-SFMBT2, Malat1, Nespas, PCGEM1, UM9-5, Zfas1, and ST7OT in HNSCC cell lines after exposure to doxorubicin and controls non-treated. Paired t-test; the graphs show relative expression, mean value with SEM; * p < 0.05, ** p < 0.01, *** p < 0.001.
Predicted molecular interactions of dysregulated lncRNAsafter irradiation or chemoexposure.
| lncRNA | Dysregulated by | Target | Biological Process/Cellular Pathway |
|---|---|---|---|
| HOTAIR | Radiotherapy | LPP, ABI2, NOS1 | Cell Cycle |
| CFLAR, REL | Apoptosis signaling pathway | ||
| FAT3 | Cadherin signaling pathway/Wnt signaling pathway | ||
| PDK1 | RAS pathway/p53 pathway | ||
| FZD3 | Wnt signaling pathway/angiogenesis/cadherin signaling pathway | ||
| SMAD2 | TGF-beta signaling pathway | ||
| FRK | Cadherin signaling pathway | ||
| SRCAP | Wnt signaling pathway | ||
| WNT2B | angiogenesis/Cadherin signaling pathway/Wnt signaling pathway | ||
| CBL | EGFR signaling pathway | ||
| SNHG5 | Radiotherapy | LPP, ABI2, HELZ, RANBP2, CEP250, CDK6, HERC1, PHC3, MYO5A | Cell Cycle |
| FZD3 | Angiogenesis/Cadherin signaling pathway/Wnt signaling pathway | ||
| CFLAR | Apoptosis signaling pathway | ||
| FAT3, FAT1 | Cadherin signaling pathway/Wnt signaling pathway | ||
| FRK | Cadherin signaling pathway | ||
| SMAD2, BMPR2 | TGF-beta signaling pathway | ||
| PTEN | Cell cycle/p53 pathway | ||
| ZMAT3, MDM4 | p53 pathway | ||
| FAT2, FER, FRK | Cadherin signaling pathway | ||
| APC | Angiogenesis/Wnt signaling pathway | ||
| NF1 | EGFR signaling pathway | ||
| Dio3os | Radiotherapy | HELZ2, NOS1, CROCC, CEP250, LPP, ABI2, HERC2, RTEL1, SMC1A, HERC1, GAS7 | Cell Cycle |
| NOTCH2 | Angiogenesis/Notch signaling pathway | ||
| PKD1 | Angiogenesis/EGFR signaling pathway | ||
| CFLAR | Apoptosis signaling pathway | ||
| FAT3, FAT2, CELSR3 | Cadherin signaling pathway/Wnt signaling pathway | ||
| CBL | EGFR signaling pathway | ||
| MYH7B, SRCAP | Wnt signaling pathway | ||
| NCOR2 | Notch signaling pathway | ||
| HAR1A | Radiotherapy | RANBP2, LPP, ABI2, HELZ, PHC3, HERC1, MYO5A | Cell Cycle |
| FZD3 | Angiogenesis | ||
| CFLAR | Apoptosis signaling pathway | ||
| FAT3, FZD3, CTNNA3 | Cadherin signaling pathway/Wnt signaling pathway | ||
| CBL | EGFR signaling pathway | ||
| BMPR2 | TGF-beta signaling pathway | ||
| HAR1B | Radiotherapy | LPP, ABI2, RSF1, HERC2, HELZ | Cell Cycle |
| FZD3 | Angiogenesis/Cadherin signaling pathway/Wnt signaling pathway | ||
| CFLAR | Apoptosis signaling pathway | ||
| FAT3 | Cadherin signaling pathway/Wnt signaling pathway | ||
| FRK, FER | Cadherin signaling pathway | ||
| PDK1 | RAS pathway | ||
| FAT1 | Wnt signaling pathway | ||
| AIR | Cisplatin | NOS1, LPP, ABI2, HELZ | Cell Cycle |
| FZD3 | Angiogenesis/Cadherin signaling pathway/Wnt signaling pathway | ||
| CFLAR | Apoptosis signaling pathway | ||
| FAT3 | Cadherin signaling pathway/Wnt signaling pathway | ||
| FRK | Cadherin signaling pathway | ||
| PDK1 | RAS pathway/p53 pathway | ||
| SMAD2, BMPR2 | TGF-beta signaling pathway | ||
| MEG3 | Cisplatin | MOB3C, RANBP2, CROCC, CEP250, CDC42BPA, LPP, ABI2, HERC2. HELZ, TPR, SMC1A, HERC1, MYO5A | Cell Cycle |
| TEP1 | Cell cycle/p53 pathway | ||
| FZD3 | Angiogenesis/Cadherin signaling pathway/Wnt signaling pathway | ||
| CFLAR, REL | Apoptosis signaling pathway | ||
| FAT1, FAT2, FAT3, CELSR2 | Cadherin signaling pathway/Wnt signaling pathway | ||
| FRK | Cadherin signaling pathway | ||
| CBL | EGFR signaling pathway | ||
| PDK1 | RAS pathway/p53 pathway | ||
| SMAD2, BMPR2 | TGF-beta signaling pathway | ||
| EP400, MYH3, MYH4, MYH7, MYH7B | Wnt signaling pathway | ||
| ATM | p53 pathway | ||
| SNHG6 | Cisplatin | LPP, ABI2, HELZ, PHC3 | Cell Cycle |
| FZD3 | Angiogenesis/Cadherin signaling pathway/Wnt signaling pathway | ||
| APC | Angiogenesis | ||
| CFLAR, REL | Apoptosis signaling pathway | ||
| FAT3 | Cadherin signaling pathway/Wnt signaling pathway | ||
| FRK | Cadherin signaling pathway | ||
| PDK1 | Ras pathway/p53 pathway | ||
| BMPR1A | TGF-beta signaling pathway/Wnt signaling pathway | ||
| SMAD2, SKIL, BMPR2 | TGF-beta signaling pathway | ||
| APC | Wnt signaling pathway | ||
| ATM | p53 pathway | ||
| PCGEM1 | Cisplatin/Doxorubicin | LPP, ABI2, PHC3 | Cell Cycle |
| FZD3 | Angiogenesis/Cadherin signaling pathway/Wnt signaling pathway | ||
| CFLAR | Apoptosis signaling pathway | ||
| FAT3 | Cadherin signaling pathway/Wnt signaling pathway | ||
| FRK, FER | Cadherin signaling pathway | ||
| PDK1 | Ras pathway/p53 pathway | ||
| BMPR2 | TGF-beta signaling pathway | ||
| ATM | p53 pathway | ||
| EgoA | Doxorubicin | FZR1, MOB3B, NIPBL, TTC29 | Cell Cycle |
| FER | Cadherin signaling pathway | ||
| KRAS | Ras pathway | ||
| MTA2 | p53 pathway | ||
| Malat1 | Doxorubicin | LPP, ABI2, HELZ, CDK6, PHC3 | Cell Cycle |
| FZD3 | Angiogenesis/Cadherin signaling pathway/Wnt signaling pathway | ||
| CFLAR, REL | Apoptosis signaling pathway | ||
| FAT3 | Cadherin signaling pathway/Wnt signaling pathway | ||
| FRK, FER | Cadherin signaling pathway | ||
| PDK1 | Ras pathway/p53 pathway | ||
| SMAD2, BMPR2 | TGF-beta signaling pathway | ||
| Zfas1 | Doxorubicin | LPP, ABI2, HELZ, PHC3 | Cell Cycle |
| FZD3 | Angiogenesis/Cadherin signaling pathway/Wnt signaling pathway | ||
| CFLAR | Apoptosis signaling pathway | ||
| FRK, FER | Cadherin signaling pathway | ||
| FAT3 | Cadherin signaling pathway/Wnt signaling pathway | ||
| ERBB4 | Cadherin signaling pathway/EGFR signaling pathway | ||
| NF1, CBL | EGFR signaling pathway |